
Elisabeth Ersvær

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6997530/publications.pdf Version: 2024-02-01



FLISABETH EDSVALD

#	Article	IF	CITATIONS
1	Digital Game-Based Support for Learning the Phlebotomy Procedure in the Biomedical Laboratory Scientist Education. Computers, 2022, 11, 59.	2.1	1
2	IL-6 Responsiveness of CD4+ and CD8+ T Cells after Allogeneic Stem Cell Transplantation Differs between Patients and Is Associated with Previous Acute Graft versus Host Disease and Pretransplant Antithymocyte Globulin Therapy. Journal of Clinical Medicine, 2022, 11, 2530.	1.0	0
3	The Female Menstrual Cycles Effect on Strength and Power Parameters in High-Level Female Team Athletes. Frontiers in Physiology, 2021, 12, 600668.	1.3	13
4	Differential expansion of circulating human MDSC subsets in patients with cancer, infection and inflammation. , 2020, 8, e001223.		104
5	State-of-the-art and Future Directions for Using Augmented Reality Head Mounted Displays for First Aid Live Training. , 2020, , .		4
6	A Pilot Study of Circulating Monocyte Subsets in Patients Treated with Stem Cell Transplantation for High-Risk Hematological Malignancies. Medicina (Lithuania), 2020, 56, 36.	0.8	4
7	Immunomodulatory Drugs Alter the Metabolism and the Extracellular Release of Soluble Mediators by Normal Monocytes. Molecules, 2020, 25, 367.	1.7	12
8	Games on Mobiles via Web or Virtual Reality Technologies: How to Support Learning for Biomedical Laboratory Science Education. Information (Switzerland), 2020, 11, 195.	1.7	16
9	mStikk - A Mobile Application for Learning Phlebotomy. , 2019, , .		4
10	wStikk – Web-based Phlebotomy Learning. , 2019, , .		0
11	Circulating monocyte subsets in multiple myeloma patients receiving autologous stem cell transplantation – a study of the preconditioning status and the course until posttransplant reconstitution for a consecutive group of patients. BMC Immunology, 2019, 20, 39.	0.9	9
12	Myeloidâ€Derived Suppressor Cells in Hematologic Diseases: Promising Biomarkers and Treatment Targets. HemaSphere, 2019, 3, e168.	1.2	41
13	Power Production and Biochemical Markers of Metabolic Stress and Muscle Damage Following a Single Bout of Short-Sprint and Heavy Strength Exercise in Well-Trained Cyclists. Frontiers in Physiology, 2018, 9, 155.	1.3	4
14	Standardization of sampling and sample preparation for analysis of human monocyte subsets in peripheral blood. Journal of Immunological Methods, 2018, 461, 53-62.	0.6	17
15	Antileukaemic effect of <scp>PI</scp> 3 <scp>K</scp> â€m <scp>TOR</scp> inhibitors in acute myeloid leukaemiaâ€gene expression profiles reveal <scp>CDC</scp> 25 <scp>B</scp> expression as determinate of pharmacological effect. British Journal of Haematology, 2014, 164, 200-211.	1.2	34
16	The combination of valproic acid, all-trans retinoic acid and low-dose cytarabine as disease-stabilizing treatment in acute myeloid leukemia. Clinical Epigenetics, 2013, 5, 13.	1.8	45
17	Distinct single cell signal transduction signatures in leukocyte subsets stimulated with khat extract, amphetamine-like cathinone, cathine or norephedrine. BMC Pharmacology & Toxicology, 2013, 14, 35.	1.0	12
18	Expression profile of heat shock proteins in acute myeloid leukaemia patients reveals a distinct signature strongly associated with <i>FLT3</i> mutation status – consequences and potentials for pharmacological intervention. British Journal of Haematology, 2012, 156, 468-480.	1.2	39

Elisabeth Ersvær

#	Article	IF	CITATIONS
19	Immunogenic apoptosis in human acute myeloid leukemia (AML): primary human AML cells expose calreticulin and release heat shock protein (HSP) 70 and HSP90 during apoptosis. Oncology Reports, 2011, 25, 1549-56.	1.2	33
20	ls there a scientific basis for a recommended standardization of collection and cryopreservation of peripheral blood stem cell grafts?. Cytotherapy, 2011, 13, 1013-1024.	0.3	13
21	Future perspectives: should Th17 cells be considered as a possible therapeutic target in acute myeloid leukemia patients receiving allogeneic stem cell transplantation?. Cancer Immunology, Immunotherapy, 2011, 60, 1669-1681.	2.0	19
22	The chemokine system in allogeneic stem-cell transplantation: a possible therapeutic target?. Expert Review of Hematology, 2011, 4, 563-576.	1.0	35
23	Combination of Intensive Chemotherapy and Anticancer Vaccines in the Treatment of Human Malignancies: The Hematological Experience. Journal of Biomedicine and Biotechnology, 2010, 2010, 1-15.	3.0	23
24	Minor diurnal and activity-induced variations in daytime peripheral blood platelet counts do not have any major impact on platelet yield by platelet apheresis. Transfusion and Apheresis Science, 2010, 43, 33-36.	0.5	2
25	Targeting the angiopoietin (Ang)/Tie-2 pathway in the crosstalk between acute myeloid leukaemia and endothelial cells: studies of Tie-2 blocking antibodies, exogenous Ang-2 and inhibition of constitutive agonistic Ang-1 release. Expert Opinion on Investigational Drugs, 2010, 19, 169-183.	1.9	36
26	The protein kinase C agonist PEP005 increases NFâ€₽̂B expression, induces differentiation and increases constitutive chemokine release by primary acute myeloid leukaemia cells. British Journal of Haematology, 2009, 145, 761-774.	1.2	26
27	Use of different DMSO concentrations for cryopreservation of autologous peripheral blood stem cell grafts does not have any major impact on levels of leukocyte-and platelet-derived soluble mediators. Cytotherapy, 2009, 11, 749-760.	0.3	26
28	In Vitro Induction of a Dendritic Cell Phenotype in Primary Human Acute Myelogenous Leukemia (AML) Blasts Alters the Chemokine Release Profile and Increases the Levels of T Cell Chemotactic CCL17 and CCL22. Journal of Interferon and Cytokine Research, 2008, 28, 297-310.	0.5	11
29	Circulating T cells derived from acute leukemia patients with severe therapy-induced cytopenia express a wide range of chemokine receptors. Hematology, 2008, 13, 329-332.	0.7	5
30	Circulating T cells in patients with untreated acute myelogenous leukemia are heterogeneous and can be activated through the CD3/TCR complex. Hematology, 2007, 12, 199-207.	0.7	14
31	The proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells. British Journal of Haematology, 2007, 136, 814-828.	1.2	115
32	T cells remaining after intensive chemotherapy for acute myelogenous leukemia show a broad cytokine release profile including high levels of interferon-γ that can be further increased by a novel protein kinase C agonist PEP005. Cancer Immunology, Immunotherapy, 2007, 56, 913-925.	2.0	25
33	Stress-induced in vitro apoptosis of native human acute myelogenous leukemia (AML) cells shows a wide variation between patients and is associated with low BCL-2:Bax ratio and low levels of heat shock protein 70 and 90. Leukemia Research, 2006, 30, 1531-1540.	0.4	53
34	In vitroeffects of native human acute myelogenous leukemia blasts on fibroblasts and osteoblasts. International Journal of Cancer, 2004, 111, 858-867.	2.3	13